Cowen reissued their buy rating on shares of Curis (NASDAQ:CRIS) in a report released on Tuesday morning.

Several other research analysts also recently commented on CRIS. ValuEngine raised shares of Curis from a sell rating to a hold rating in a report on Thursday, May 31st. Zacks Investment Research downgraded shares of Curis from a buy rating to a hold rating in a report on Tuesday, June 5th. Finally, SunTrust Banks dropped their price objective on shares of Curis to $8.00 and set a buy rating for the company in a report on Friday, August 3rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Curis presently has an average rating of Buy and an average price target of $18.75.

CRIS opened at $1.59 on Tuesday. Curis has a 52 week low of $1.36 and a 52 week high of $8.70. The company has a debt-to-equity ratio of 4.43, a quick ratio of 3.01 and a current ratio of 3.01.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.15. Curis had a negative net margin of 407.29% and a negative return on equity of 225.77%. The business had revenue of $2.36 million during the quarter, compared to the consensus estimate of $2.41 million. equities research analysts expect that Curis will post -1.18 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the stock. LMR Partners LLP bought a new position in shares of Curis in the 2nd quarter valued at about $124,000. Paloma Partners Management Co bought a new position in shares of Curis in the 2nd quarter valued at about $223,000. Millennium Management LLC bought a new position in shares of Curis in the 2nd quarter valued at about $540,000. Candriam Luxembourg S.C.A. bought a new position in shares of Curis in the 1st quarter valued at about $523,000. Finally, Sio Capital Management LLC bought a new position in shares of Curis in the 1st quarter valued at about $545,000. 33.49% of the stock is owned by hedge funds and other institutional investors.

About Curis

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Featured Article: How to Use the New Google Finance Tool

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.